CURE vs QULL

Key Takeaways

• CURE delivers 3x daily leveraged exposure to the U.S. healthcare sector, concentrating risk in pharmaceuticals, biotechnology, and providers, while QULL provides 2x leveraged exposure to a sector-neutral quality factor index spanning multiple industries.
• Both products employ leverage, increasing volatility and the potential for compounding decay over extended holding periods compared with unleveraged alternatives.
• CURE carries a 0.94% expense ratio and relies primarily on swaps for its leveraged healthcare allocation, whereas QULL incurs a 0.95% tracking fee plus variable financing costs as an exchange-traded note (ETN).
• CURE offers pure-play thematic exposure to healthcare innovation and demographics, while QULL emphasizes high-quality companies with strong profitability and low debt across sectors.
• Structural differences in leverage magnitude, underlying index construction, and product type (ETF versus ETN) drive divergent risk profiles and rebalancing dynamics.
• Investors seeking sector-specific amplification may favor CURE, whereas those targeting quality-factor momentum across the broad market may prefer QULL.

Introduction

Direxion Daily Healthcare Bull 3X Shares (CURE) and ETRACS 2x Leveraged MSCI US Quality Factor TR ETN (QULL) represent distinct leveraged strategies that appeal to investors pursuing amplified returns in specific market segments. CURE targets the healthcare sector exclusively, while QULL applies leverage to a quality-factor index that is sector-neutral. They do not compete head-to-head but serve as alternative vehicles for investors with different thematic or factor-based objectives in the current environment of sector rotation and factor performance cycles.

Direxion Daily Healthcare Bull 3X Shares (CURE) Overview

CURE is a leveraged exchange-traded fund (ETF) that seeks daily investment results, before fees and expenses, of 300% of the performance of the Health Care Select Sector Index. The fund maintains approximately 60–70 positions through a combination of swaps and direct holdings, with 100% allocation to the healthcare sector. Top holdings in the underlying index typically include Eli Lilly, Johnson & Johnson, AbbVie, Merck, and UnitedHealth Group. The expense ratio stands at 0.94%. As a daily-reset leveraged product, CURE rebalances each trading day to maintain its target exposure, which can lead to significant tracking differences over multi-day periods.

ETRACS 2x Leveraged MSCI US Quality Factor TR ETN (QULL) Overview

QULL is an exchange-traded note (ETN) that seeks to deliver two times the compounded quarterly performance of the MSCI USA Sector Neutral Quality GR USD Index, less fees and financing costs. The product provides leveraged exposure to U.S. equities screened for quality characteristics such as high return on equity, stable earnings growth, and low financial leverage, while remaining sector-neutral. It carries a 0.95% annual tracking fee plus a financing fee tied to short-term rates. Because it is structured as an ETN, investors bear the credit risk of the issuer in addition to market risk. Rebalancing occurs quarterly to align with the index methodology.

Industry and Thematic Backdrop

The healthcare sector continues to benefit from long-term demographic trends, including aging populations and advances in biotechnology and pharmaceuticals. Quality-factor strategies, by contrast, attract capital during periods of economic uncertainty when investors prioritize companies with durable balance sheets and consistent profitability. Macroeconomic drivers such as interest-rate expectations, regulatory developments in drug pricing, and broader equity-market volatility influence capital flows into both leveraged healthcare exposure and quality-tilted portfolios. Sector rotation between defensive healthcare and broader market quality names remains a key dynamic for both products.

Performance and Positioning Comparison

In recent market cycles, CURE has exhibited higher volatility due to its 3x leverage and single-sector focus, amplifying moves tied to healthcare earnings reports and regulatory news. QULL, with 2x leverage applied to a diversified quality index, has shown somewhat lower sector-specific volatility but remains sensitive to shifts in investor preference for quality characteristics across the market. Relative positioning depends on whether healthcare earnings momentum or broad-market quality-factor leadership dominates during earnings seasons and macroeconomic shifts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your ETF research.

Tickeron AI Verdict

Based on structural characteristics, CURE offers more concentrated leverage within a single high-growth sector but carries elevated volatility and daily-reset decay risk. QULL provides moderate leverage across a diversified quality-factor universe with sector neutrality, potentially offering smoother exposure during rotations. Tickeron’s AI would currently assign a modest probabilistic edge to QULL for investors prioritizing factor diversification over pure sector amplification, given its lower leverage multiple and broader holdings profile.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations